



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) MARIANI SABRINA
Address(es) Azienda Ospedaliero-Universitaria Sant'Andrea, UOC Ematologia, Via di Grottarossa 1035-1039 Rome, Italy
Fax(es)
E-mail sa.mariani@uniroma1.it, samariani@omceoromapec.it,
ematrial.santandrea@gmail.com
Nationality Italian
Gender Female

Occupational field Haematology: clinical and scientific activity in Haematology

Work experience

Dates	<u>November 2020-now</u>
Occupation or position held	UOC Haematology AOU Sant'Andrea Rome, Italy
Main activities and responsibilities	
Name and address of employer	Faculty of Medicine, "Sapienza" University of Rome
Sector	Clinical and research activity in adult age hematology
Dates	<u>November 2018- November 2020</u>
Occupation or position held	UOC Haematology AOU Sant'Andrea Rome, Italy
Main activities and responsibilities	
Name and address of employer	Faculty of Medicine, "Sapienza" University of Rome
Sector	Medical doctor in training Clinical and research activity in adult age hematology
Dates	<u>November 2016- November 2018</u>
Occupation or position held	Hematology, Department of Translational and Precision Medicine, University
Main activities and responsibilities	'Sapienza Rome, Italy
Name and address of employer	Faculty of Medicine, "Sapienza" University of Rome
Sector	Medical doctor in training Clinical and research activity in pediatric and adult age hematology

Dates	<u>May 2013-July 2016</u>
Occupation or position held	Hematology, Department of Translational and Precision Medicine, University
Main activities and responsibilities	“Sapienza” Rome (Paediatrics Hematology)
Name and address of employer	Faculty of Medicine, “Sapienza” University of Rome
Sector	Student
	Clinical and research activity, degree thesis in Chronic Myeloid Leukemia in children.
Education and training	<u>November 2020</u>
	Faculty of Medicine, “Sapienza” University of Rome, Degree in Haematology, Department of Translational and Precision Medicine, University “Sapienza” Rome, Italy, 70/70 cum laude
	<u>February 2016:</u>
	Qualification to practice, "Sapienza" University of Rome.
	<u>July 2015</u>
	Faculty of Medicine, “Sapienza” University of Rome, degree 110/110 cum laude
	<u>September 2004- July 2009</u>
	Classic High School “Ugo Foscolo” in Albano Laziale, Rome Degree 100/100
Personal skills and competences	Excellent skills in individual and team working. Excellent skills in organizing work project. Excellent skills in communication with colleagues and patients.
Mother tongue(s)	Italian
Other language(s)	
Self-assessment	
European level (*)	
Language	
Language	

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	English	C1	English	C1	English	C1	English	C1	English
A2	French	B1	French	A2	French	A2	French	A2	French

Additional information

EDITORIAL ACTIVITIES:

“Very late acute myeloid leukemia relapse: clinical features, treatment and outcome Article. Leukemia and Lymphoma, 2020.

“Gaucher Disease and Myelofibrosis: A Combined Disease or a Misdiagnosis?” Acta haematologica, 2018

“Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.” Haematologica, 2018

“Treatment free remission after Imatinib discontinuation is possible in paediatric patients with chronic myeloid leukemia” British Journal of Haematology, 2014

“Chronic myeloid leukemia in childhood: clinical features and therapeutic strategies before tyrosine kinase inhibitor. a succesful medical history” 7th international symposium on acute promyelocytic leukemia, poster 2017

“Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse B Large Cell Lymphoma with Cardiac Involvement” Hemato 2021.

“Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP)” Blood Cancer J. 2018 (collaborator)

“Response to High Dose Imatinib and Long-Term Outcome in Children and Adolescents with Previously Untreated Chronic Myeloid Leukemia in Chronic Phase: the Italian Experience” Poster ASH 2014

“MRP4 Expression and Platelet Activation in Children and Adolescents with Different Subtypes of Primary Thrombocythemia” Poster ASH 2014.

FIELD OF INTEREST: Hodgkin and non- Hodgkin lymphoma in adults. Autologous stem cells transplantations in haematology. Thrombotic thrombocytopenic purpura in adults. Lymphoproliferative diseases in adults. Myeloproliferative disease in adults.

SUB-INVESTIGATOR

-FIL Ri-CHOP Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥ 2).

-INKL (EORTC) An international field study for the reliability and validity of the Phase IV EORTC Quality of Life modules for patients with Hodgkin's Lymphoma (EORTC QLQ-HL27), high-grade non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29), low-grade non-Hodgkin's Lymphoma (EORTC QLQ-NHL-LG20), and Chronic Lymphocytic Leukaemia (EORTC QLQ-CLL17).

-MOR208C213 (RE-MIND2) An observational retrospective cohort study of systemic therapies for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), to compare outcomes to those from Tafasitamab + Lenalidomide in the L-MIND study MOR208C213 (RE-MIND2)

-FIL- DEVEC: "Studio di fase II sull'uso della chemioterapia metronomica in pazienti anziani (>65 anni) non fit con linfoma a cellule B aggressivo".

-ML41215 (URBAN): "Studio non interventistico, retrospettivo e prospettico, multicentrico, a singolo braccio, per la valutazione di efficacia e sicurezza di obinutuzumab nei pazienti con linfoma follicolare in fase avanzata non precedentemente trattato".

-Real-MM: "Studio randomizzato, multicentrico, in aperto che compara due trattamenti standard, bortezomib-melfalan-prednisone (VMP) vs lenalidomide-desametasone (Rd) in pazienti non eleggibili al trapianto di cellule staminali (ASCT) affetti da mieloma multiplo (MM)".

-RELEVANCE RV-FOL-GELARC-0683 A phase 3 open label randomized study to compare the efficacy and safety of Rituximab plus Lenalidomide (CC-5013) versus Rituximab plus Chemotherapy followed by Rituximab in subjects with previously untreated follicular Lymphoma.

- SUSTRENIM GIMEMA CML1415. Remissione sostenuta senza trattamento nella leucemia mieloide cronica BCR-ABL+: uno studio prospettico che confronta Nilotinib versus Imatinib con passaggio a Nilotinib in assenza di risposta ottimale.

- A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment.

- CINC424BIC04. An International Multi-Centric Observational Study on the Use of Ruxolitinib in the Treatment of Patients with Polycythemia Vera resistant or intolerant to hydroxyurea.

-GIMEMA ALLIANCE. "An onLine-pLatform to improve patient-centered care during the COVID-19 pAndemic: a GIMEMA surveillaNce program in hematologic malignanciEs".

I agree with the treatment of my personal data ref D.Lgs 196/2003 and GDPR 679/2016

Rome, 07/06/2021